4.6 Article

Constitutive activation of the alternative NF-κB pathway disturbs endochondral ossification

期刊

BONE
卷 121, 期 -, 页码 29-41

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2019.01.002

关键词

Chondrocytes; Alternative NF-kappa B pathway; Endochondral ossification

资金

  1. Kyushu Dental University Internal Grants
  2. Research Fellowship for Young Scientists [JP16J09963]

向作者/读者索取更多资源

Endochondral ossification is important for skeletal development. Recent findings indicate that the p65 (RelA) subunit, a main subunit of the classical nuclear factor-kappa B (NF-kappa B) pathway, plays essential roles in chondrocyte differentiation. Although several groups have reported that the alternative NF-kappa B pathway also regulates bone homeostasis, the role of the alternative NF-kappa B pathway in chondrocyte development is still unclear. Here, we analyzed the in vivo function of the alternative pathway on endochondral ossification using p100-deficient (p100(-/-)) mice, which carry a homozygous deletion of the COON-terminal ankyrin repeats of p100 but still express functional p52 protein. The alternative pathway was activated during the periarticular stage in wild-type mice. p100(-/-) mice exhibited dwarfism, and histological analysis of the growth plate revealed abnormal arrangement of chondrocyte columns and a narrowed hypertrophic zone. Consistent with these observations, the expression of hypertrophic chondrocyte markers, type X collagen (ColX) or matrix metalloproteinase 13, but not early chondrogenic markers, such as Col II or aggrecan, was suppressed in p100(-/-) mice. An in vivo BrdU tracing assay clearly demonstrated less proliferative activity in chondrocytes in p100(-/-) mice. These defects were partly rescued when the RelB gene was deleted in p100(-/-) mice. Taken together, the alternative NF-kappa B pathway may regulate chondrocyte proliferation and differentiation to maintain endochondral ossification.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据